




Antimicrobial Stewardship Collaborative
of South Carolina



e. In obese patients (BMI >30 kg/m²), consider: Amoxicillin/clavulanate 500/125 mg TID, Cephalexin 1000 mg TID or QID, Cefadroxil 1000 mg BID, SMZ-TMP 8-10 mg/kg/day (adjusted BW) in divided doses.⁹

Animal/Human Bites

Prevention of Infection

Treatment of Infection

Presence of Risk Factors?

- Immunocompromised
- Asplenic
- Advanced liver disease
- Pre-existing resultant edema of the affected area
- Moderate to severe injuries to hand/face that may have penetrated the periosteum or joint capsule (e.g., penetrating cat bite)

No

Yes

No prophylactic antibiotics indicated

Prophylactic antibiotics indicated^h

Preferred: Amoxicillin/clavulanate 875/125 mg PO BID^e

Alternatives:

- Doxycycline 100 mg PO BID
- Cefuroxime 500 mg PO BID plus metronidazole 500 mg PO TID
- SMZ-TMP 1-2 DS PO BID plus metronidazole 500 mg PO BID - TID^e

Duration: 3-5 days

Vaccination Consideration (if indicated)

- Consider tetanus toxoid vaccine
- Consider post-exposure rabies prophylaxis with consultation of local health officials/infectious diseases (see www.cdc.gov/rabies/exposure/animals/)

Preferred: Amoxicillin/clavulanate 875/125 mg PO BID^e

Alternatives:

- Animal bites only:
 - Doxycycline 100 mg PO BID
 - Cefuroxime 500 mg PO BID plus metronidazole 500 mg PO BID - TID
 - SMZ-TMP 1-2 DS PO BID plus metronidazole 500 mg PO BID - TID^e
- Human bites only:
 - Levofloxacin 750 mg PO daily plus metronidazole 500 mg PO BID - TID

Duration: 5-10 daysⁱ

Vaccination Consideration (if indicated)

- Consider tetanus toxoid vaccine
- Consider post-exposure rabies prophylaxis with consultation of local health officials/infectious diseases (see www.cdc.gov/rabies/exposure/animals/)

e. In obese patients (BMI >30 kg/m²), consider: Amoxicillin/clavulanate 500/125 mg TID, Cephalexin 1000 mg TID or QID, Cefadroxil 1000 mg BID, SMZ-TMP 8-10 mg/kg/day (adjusted BW) in divided doses.⁹

h. Prophylactic regimen should be initiated within 12-24 hours of injuries. Consider extending the course to treatment duration (e.g. 5 -10 days) if the injuries become infectious after completing prophylactic course.

i. Treatment duration may be extended due to lack of clinical response or in an immunocompromised patient.

References

1. Wible K, tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. *Pediatr Infect Dis J* 2003; 22(4):315-23.
2. Gooch WM 3rd, Kaminester L, Cole GW, et al. Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures. *Dermatologica* 1991; 183(1):36-43.
3. Henness DM and Gordon WE. Effective once- or twice-daily treatment of skin and skin structure infections with a new cephalosporin (cefadroxil). *Infection* 1980; S633-7
4. Ballantyne F. Cefadroxil in the treatment of skin and soft tissue infections. *J Antimicrob Chemother* 1982; Suppl. B:142-7.
5. Gatti M, Raschi E, de Ponti F. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. *Eur J Clin Pharmacol* 2021. 77(2):233-39.
6. Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014; 59(2):e10-52.
7. Sartelli M, Guirao X, Hardcastle TC, et al. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. *World J Emerg Surg* 2018; 13:58. doi:10.1186/s13017-018-0219-9.
8. CLEOCIN HYDROCHLORIDE – clindamycin hydrochloride capsule [package insert]. Sun Pharmaceutical Industries, Inc: 2009.
9. Meng L, Mui E, Holubar MK, and Deresinski SC. Comprehensive Guidance for Antibiotic Dosing in Obese Adults. *Pharmacotherapy* 2017; 37(11):1415-31.

Footnotes

- a. For impetigo only: in the absence of numerous lesions or outbreaks affecting several people, can consider mupirocin ointment (apply to lesions BID) x5 days.
- b. Consider coverage against MRSA: penetrating trauma, evidence of MRSA infection elsewhere, nasal colonization with MRSA, or IVDU.
- c. If coverage for both *Streptococcus* spp. and MRSA is desired: linezolid or SMZ-TMP monotherapy, or doxycycline with a beta-lactam (e.g. cephalexin) combination therapy.
- d. Blood cultures and cutaneous aspiration/biopsies prior to administration of antibiotics for erysipelas and cellulitis are recommended for patients with malignancy on chemotherapy, neutropenia, severe cell-mediated immunodeficiency, immersion injuries, and animal bites.
- e. In obese patients (BMI >30 kg/m²), consider: Amoxicillin/clavulanate 500/125 mg TID, Cephalexin 1000 mg TID or QID, Cefadroxil 1000 mg BID, SMZ-TMP 8-10 mg/kg/day (adjusted BW) in divided doses.⁹
- f. Consider avoiding the use of linezolid in patient with the following risk factors: baseline platelet level of <50 x10³/mm³, the use of monoamine oxidase inhibitor within the last 2 weeks, and concomitant use of agents high risk for serotonin syndrome including citalopram, escitalopram, and methadone.⁵
- g. Cultures of pus from abscesses, carbuncles, or furuncles prior to administration of antibiotics are recommended, but treatment without them is reasonable
- h. Prophylactic regimen should be initiated within 12-24 hours of injuries. Consider extending the course to treatment duration (e.g. 5 -10 days) if the injuries become infectious after completing prophylactic course.
- i. Treatment duration may be extended due to lack of clinical response or in an immunocompromised patient.

-
- Recommendations are modified from the Infectious Disease Society of America (IDSA) 2014 SSTI Management and World Society of Emergency Surgery (WSES)/Surgical Infection Society Europe (SIS-E) 2018 Consensus for the Management of SSTI.⁶⁻⁷
 - All dosages provided assume normal renal and hepatic function.
 - Clindamycin has a black box warning for high risk of severe colitis which may end fatally. Consider reserving the use of clindamycin for serious infections for which less toxic antimicrobial agents are inappropriate.⁸
-